Day Return
YTD Return
1-Year Return
3-Year Return
5-Year Return
Note: Industry performance is calculated based on the previous closing price of all industry constituents
Largest Companies in This Industry
Name | Last Price | 1Y Target Est. | Market Weight | Market Cap | Day Change % | YTD Return | Avg. Analyst Rating |
---|---|---|---|---|---|---|---|
734.97 | 855.36 | 31.72% | Buy | ||||
149.27 | 172.98 | 16.32% | Buy | ||||
127.51 | 141.42 | 14.67% | Buy | ||||
163.79 | 183.53 | 13.17% | Buy | ||||
311.29 | 306.20 | 7.58% | Buy | ||||
27.81 | 31.10 | 7.15% | Buy | ||||
43.99 | 52.57 | 4.05% | Hold | ||||
64.78 | 82.04 | 3.67% | Buy | ||||
217.51 | 284.76 | 1.44% | Buy | ||||
19.61 | 21.75 | 0.23% | Hold |
Investing in the Drug Manufacturers - General Industry
Start Investing in Drug Manufacturers - General Through These Companies
Top Performing Companies
Name | Last Price | 1Y Target Est. | YTD Return |
---|---|---|---|
19.61 | 21.75 | ||
734.97 | 855.36 | ||
127.51 | 141.42 | ||
311.29 | 306.20 | ||
163.79 | 183.53 |
High Growth Companies
Name | Last Price | Growth Estimate | YTD Return |
---|---|---|---|
127.51 | |||
734.97 | |||
27.81 | |||
217.51 | |||
19.61 |
Drug Manufacturers - General Research
Discover the Latest Analyst and Technical Research for This Industry
Analyst Report: Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
RatingPrice TargetAnalyst Report: Pfizer Inc.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
RatingPrice TargetAnalyst Report: GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
RatingPrice TargetAnalyst Report: Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
RatingPrice Target